Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Background. We investigated the level of soluble adhesion molecules in diabetic patients and the effect of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone on plasma levels of adhesion molecules and an inflammation marker in type 2 diabetic patients with coronary arter...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/548178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564665199099904 |
|---|---|
| author | Guang Wang Zhe Zhang Jie Yu Fuchun Zhang Liyun He Jinru Wei Jieming Mao Xian Wang |
| author_facet | Guang Wang Zhe Zhang Jie Yu Fuchun Zhang Liyun He Jinru Wei Jieming Mao Xian Wang |
| author_sort | Guang Wang |
| collection | DOAJ |
| description | Background. We investigated the level of soluble adhesion molecules in diabetic patients and the effect of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone on plasma levels of adhesion molecules and an inflammation marker in type 2 diabetic patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Methods. A total of 116 diabetic patients with CAD who had undergone PCI were randomized to receive rosiglitazone (4 mg/d) or not for 6 months. Plasma levels of soluble intercellular adhesion molecules (sICAM-1) and P-selectin (sP-selectin) were measured on ELISA. Results. After 6-month rosiglitazone treatment, plasma levels of sICAM-1 were lower than baseline and control group levels (370.4 (332.4–421.9) pg/mL versus 423.5 (327.4–500.3) pg/mL and 404.6 (345.2–483.4) pg/mL, P<.001). In addition, plasma levels of C-reactive protein were significantly reduced from baseline levels. However, plasma level of sP-selectin was not significantly lowered with rosiglitazone treatment than with control treatment after 6-month follow-up. Conclusions. Rosiglitazone reduces chronic inflammatory responses and improves levels of markers of endothelial dysfunction in patients with diabetes and CAD. PPAR-γ agonist may have a beneficial effect on the vascular endothelium through its anti-inflammatory mechanism and may be useful as therapy in patients undergoing PCI. |
| format | Article |
| id | doaj-art-1a609ed85b504306bb9854e56989b844 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-1a609ed85b504306bb9854e56989b8442025-02-03T01:10:23ZengWileyPPAR Research1687-47571687-47652008-01-01200810.1155/2008/548178548178Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery DiseaseGuang Wang0Zhe Zhang1Jie Yu2Fuchun Zhang3Liyun He4Jinru Wei5Jieming Mao6Xian Wang7Institute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Cardiovascular Surgery, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaInstitute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, ChinaBackground. We investigated the level of soluble adhesion molecules in diabetic patients and the effect of the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone on plasma levels of adhesion molecules and an inflammation marker in type 2 diabetic patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Methods. A total of 116 diabetic patients with CAD who had undergone PCI were randomized to receive rosiglitazone (4 mg/d) or not for 6 months. Plasma levels of soluble intercellular adhesion molecules (sICAM-1) and P-selectin (sP-selectin) were measured on ELISA. Results. After 6-month rosiglitazone treatment, plasma levels of sICAM-1 were lower than baseline and control group levels (370.4 (332.4–421.9) pg/mL versus 423.5 (327.4–500.3) pg/mL and 404.6 (345.2–483.4) pg/mL, P<.001). In addition, plasma levels of C-reactive protein were significantly reduced from baseline levels. However, plasma level of sP-selectin was not significantly lowered with rosiglitazone treatment than with control treatment after 6-month follow-up. Conclusions. Rosiglitazone reduces chronic inflammatory responses and improves levels of markers of endothelial dysfunction in patients with diabetes and CAD. PPAR-γ agonist may have a beneficial effect on the vascular endothelium through its anti-inflammatory mechanism and may be useful as therapy in patients undergoing PCI.http://dx.doi.org/10.1155/2008/548178 |
| spellingShingle | Guang Wang Zhe Zhang Jie Yu Fuchun Zhang Liyun He Jinru Wei Jieming Mao Xian Wang Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease PPAR Research |
| title | Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease |
| title_full | Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease |
| title_fullStr | Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease |
| title_full_unstemmed | Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease |
| title_short | Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease |
| title_sort | antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule 1 level in type 2 diabetic patients with coronary artery disease |
| url | http://dx.doi.org/10.1155/2008/548178 |
| work_keys_str_mv | AT guangwang antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT zhezhang antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT jieyu antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT fuchunzhang antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT liyunhe antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT jinruwei antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT jiemingmao antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease AT xianwang antidiabeticrosiglitazonereducessolubleintercellularadhesionmolecule1levelintype2diabeticpatientswithcoronaryarterydisease |